Celebrating 4 Years of EndoPredict in India
At Positive Bioscience, our mission has always been to provide the highest-quality of testing to cancer patients to help secure the best possible outcome for each and every patient. With our mission in mind we partnered Myriad Genetics (USA), the founder of BRCA testing and a world leader in molecular diagnostics to bring their testing to India for the first time in 2015. Today in 2019 we can look back at our partnership with pride in helping hundreds and hundreds of Indian patients.
To celebrate 4 years of our exclusive partnership: We want to share the success story of EndoPredict testing. EndoPredict is a breast cancer recurrence test used as a 15 year treatment planning tool for women suffering from early breast cancer and is recommended by almost all leading international cancer treatment guidelines.
EndoPredict is the only test which answers three critical clinical questions:
1. What is the risk of breast cancer recurrence?
2. Can chemotherapy be safely avoided?
3. Will hormone therapy be required after 5 years?
After four years of EndoPredict being available in India the results speak for themselves. EndoPredict has enabled hundreds of Indian women to safely forgo chemotherapy by categorizing them as a low-risk of breast cancer recurrence! Additionally, EndoPredict is used by nearly all the leading hospitals in India.
We hope to help many more women in their struggle against breast cancer through EndoPredict.
